IOVA Q4 2025 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$87M+17.7% YoY

Gross Profit

$187M215.9% margin

Operating Income

-$73M-84.7% margin

Net Income

-$72M-82.9% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

+28.6%

Cash Flow

Operating Cash Flow

-$53M

Free Cash Flow

-$62M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$913M

Total Liabilities

$215M

Stockholders' Equity

$699M

Cash & Equivalents

$163M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$87M	$74M	+17.7%
Gross Profit	$187M	$28M	+565.3%
Operating Income	-$73M	-$87M	+15.1%
Net Income	-$72M	-$79M	+8.5%

Geographic Segments

UNITED STATES

$85M99%

Non-US

$1M1%